Gastric Cancer Indication
Gastric cancer is the fourth most commonly diagnosed cancer. Recently, trastuzumab has shown to improve the survival of patients with advanced gastric cancer. Dako has also received approval from the U.S. FDA to expand the use of the HercepTest™ and HER2 pharmDx™ Kits to include patients with metastatic gastric or gastricesophageal junction adenocarcinoma*.
Leading pathologists endorse and use HercepTest™: See and hear why!
(*Lancet 2010; 376:687-07)
Dako Gastric Cancer Literature
Dako provides a variety of material for HER2 testing in Gastric Cancer.
Click on this link for information on products, test algorithm and more:
Would you like further information?
Please contact your local Dako representative for additional material:
HER2 FISH material: